MARCH8 Activators
MARCH8 activators include a variety of chemical compounds that might indirectly influence the functional activity of MARCH8 through modulation of the ubiquitin-proteasome system, immune regulation, or cellular stress mechanisms. Compounds such as MG-132 [Z-Leu- Leu-Leu-CHO], Bortezomib, and Lactacystin are proteasome inhibitors that increase the pool of ubiquitinated proteins, potentially enhancing the substrates available for MARCH8's E3 ubiquitin ligase activity. This increase could lead to enhanced ubiquitination and regulatory processes where MARCH8 is involved, particularly in immune regulation and the modulation of membrane protein expression. Immunomodulatory compounds like Interferon-gamma and Lenalidomide might indirectly boost MARCH8 activity by enhancing immune responses or altering the cellular microenvironment, thereby increasing the need for MARCH8's regulatory roles in these pathways. Similarly, agents like Tunicamycin and Piperlongumine, which induce cellular stress, could impact the expression or stability of MARCH8, potentially making it more active in tagging proteins for ubiquitination during stress responses.
Inhibitors of specific signaling pathways, such as NF-κB inhibitors, and compounds affecting protein folding and stability, like Curcumin or Betulinic Acid, could indirectly enhance MARCH8 activity by creating conditions that require extensive regulation of protein turnover and stability, areas where ubiquitination is crucial. Through these diverse mechanisms, the listed compounds collectively contribute to the potential modulation of MARCH8's activity, highlighting the intricate network of cellular signaling, protein regulation, and immune system interaction in which MARCH8 operates. These activators underscore the complexity of targeting specific protein functions within the ubiquitin-proteasome system and the broader regulatory roles it plays in cellular physiology.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
MG-132 [Z-Leu- Leu-Leu-CHO] | 133407-82-6 | sc-201270 sc-201270A sc-201270B | 5 mg 25 mg 100 mg | $56.00 $260.00 $980.00 | 163 | |
MG-132 [Z-Leu- Leu-Leu-CHO] is a proteasome inhibitor known to increase cellular levels of ubiquitinated proteins. By inhibiting proteasomal degradation, MG132 might indirectly enhance the functional activity of MARCH8 by increasing the substrate availability for ubiquitination, potentially enhancing its E3 ligase activity. | ||||||
Thalidomide | 50-35-1 | sc-201445 sc-201445A | 100 mg 500 mg | $109.00 $350.00 | 8 | |
Thalidomide and its derivatives, known as immunomodulatory imide drugs (IMiDs), can affect the ubiquitin-proteasome system and have been found to enhance the degradation of specific proteins. They could influence MARCH8 activity by altering the balance of protein degradation and ubiquitination in cells. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $132.00 $1064.00 | 115 | |
Bortezomib is a proteasome inhibitor used primarily in the treatment of multiple myeloma and other malignancies. By preventing the degradation of ubiquitinated proteins, it could indirectly increase the functional activity of MARCH8 by raising the levels of its substrates, potentially enhancing ubiquitination processes. | ||||||
Lactacystin | 133343-34-7 | sc-3575 sc-3575A | 200 µg 1 mg | $165.00 $575.00 | 60 | |
Lactacystin is a specific inhibitor of the proteasome that can prevent the degradation of ubiquitinated proteins. This could lead to increased levels of substrates for MARCH8, potentially enhancing its activity in tagging proteins for degradation. | ||||||
Lenalidomide | 191732-72-6 | sc-218656 sc-218656A sc-218656B | 10 mg 100 mg 1 g | $49.00 $367.00 $2030.00 | 18 | |
Lenalidomide, one of the IMiDs, affects the immune system and the microenvironment of tumor cells. It might influence the activity of MARCH8 by modulating the cellular environment, especially in contexts related to immune regulation or tumorigenesis. | ||||||
Tunicamycin | 11089-65-9 | sc-3506A sc-3506 | 5 mg 10 mg | $169.00 $299.00 | 66 | |
Tunicamycin inhibits N-linked glycosylation, affecting protein folding and stability. The resulting stress on the protein quality control system could indirectly enhance MARCH8 activity by upregulating the ubiquitination of misfolded or unassembled proteins. | ||||||
Curcumin | 458-37-7 | sc-200509 sc-200509A sc-200509B sc-200509C sc-200509D sc-200509F sc-200509E | 1 g 5 g 25 g 100 g 250 g 1 kg 2.5 kg | $36.00 $68.00 $107.00 $214.00 $234.00 $862.00 $1968.00 | 47 | |
Curcumin is a bioactive compound from turmeric with multiple cellular effects, including modulation of inflammation and oxidation. It might indirectly influence MARCH8 activity by altering cellular signaling pathways and stress responses, areas where MARCH8 could play a regulatory role. | ||||||
Pyrrolidinedithiocarbamic acid ammonium salt | 5108-96-3 | sc-203224 sc-203224A | 5 g 25 g | $32.00 $63.00 | 11 | |
NF-κB is a key regulator of immune response and inflammation. Inhibitors of NF-κB like Pyrrolidinedithiocarbamic acid ammonium salt might indirectly affect MARCH8 activity by modulating immune signaling pathways and the expression of immune regulatory proteins. | ||||||
Epoxomicin | 134381-21-8 | sc-201298C sc-201298 sc-201298A sc-201298B | 50 µg 100 µg 250 µg 500 µg | $134.00 $215.00 $440.00 $496.00 | 19 | |
Epoxomicin is a potent and selective proteasome inhibitor. By inhibiting protein degradation, it might enhance MARCH8's ubiquitination activity by increasing the levels of proteins available for ubiquitination. | ||||||
Betulinic Acid | 472-15-1 | sc-200132 sc-200132A | 25 mg 100 mg | $115.00 $337.00 | 3 | |
Betulinic Acid is known for its therapeutic potential, including anti-inflammatory and antiviral effects. It might influence MARCH8 activity indirectly by modulating cellular stress responses or pathways in which MARCH8 is involved, particularly those related to protein ubiquitination. | ||||||